to compare the incidence of brain metastases of advanced non-small cell lung cancer (nScLc) treated with systemic cytotoxic chemotherapy (CC) and targeted therapy (TT), we performed a large-scale, retrospective, nationwide, cohort study. The population data were extracted from the Health Insurance Review and Assessment Service of Korea database from January 1, 2011, to November 30, 2016. Of the 29,174 patients newly diagnosed with stage IIIB or IV NSCLC who received systemic treatment, we investigated the initial and subsequent incidence of brain metastases. Besides, among 22,458 patients without initial brain metastasis, the overall cumulative incidence of subsequent brain metastases was compared according to systemic treatment administered. In total, 1,126 (5.0%) patients subsequently developed brain metastasis. The overall cumulative incidence of brain metastasis was significantly higher in the TT group than in the CC group (1-year cumulative incidence: 8.7% vs. 3.8%; 3-year: 17.2% vs. 5.0%; P < 0.001). Younger age, female sex, and first-line TT were significant risk factors for subsequent brain metastasis. In conclusion, the overall cumulative incidence of brain metastasis was significantly higher in patients received TT as the first-line treatment than in those received CC.
Study population. The data-mining scheme used in this study is shown in Fig. 2 . Being compulsory, Korean health insurance covers the entire population, HIRA provides information on medical fees and assesses the quality of healthcare services provided to the Korean population. Thus, HIRA data includes all ICD-10 diagnostic codes and billing codes of all medical services, such as diagnostic procedures, treatment modalities (such as drug prescriptions, radiotherapy or surgery), provided to the entire population of Korea.
To select the appropriate patient cohort, we performed several queries. In the first query, to discriminate newly diagnosed NSCLC patients, the billing codes of treatment and drugs in 446,601 patients with a C34 ICD-10 code were queried. The treatment billing codes consisted of lung surgery and radiotherapy (body or brain), and the drugs prescribed were paclitaxel, pemetrexed, gemcitabine, docetaxel, erlotinib, afatinib, ceritinib, crizotinib, and gefitinib. In total, 72,043 patients were identified using the above queries, of which 25,834 were filtered out as they had received chemotherapy not used for NSCLC or had other types of cancer. The remaining 46,209 patients were selected as newly diagnosed NSCLC patients between January 1 2011 and Nov 30 2016.
We regarded patients who underwent lung surgery as having early stage NSCLC, those who received radiotherapy of the lung parenchyma as having locally advanced NSCLC, and patients who received only systemic CC or TT appropriate for NSCLC as having metastatic or recurrent disease. To verify the survival outcome reliability of NSCLC patients, a survival analysis was performed according to treatment pattern. A Kaplan-Meier analysis showed the median survival duration and 5-year survival rate to be 75.6 months (95% confidence interval [CI], 71.4-81.1) and 57.19 ± 0.72%, 26.3 months (95% CI, 25.4-27.3) and 26.01 ± 0.66%, and 13.1 months (95% CI, 12.9-13.3) and 11.56 ± 0.23% in 46,209 patients received operation, lung radiotherapy, and systemic chemotherapy, respectively (Supplemental Fig. 1 ). These findings are comparable with those of a recent study of NSCLC patients 7 .
Next, to identify patients with stage IIIB or IV NSCLC the following queries were used: (1) first-ever administration of targeted therapeutics such as afatinib, ceritinib, crizotinib, erlotinib, or gefitinib; OR (2) cytotoxic chemotherapeutics such as paclitaxel, pemetrexed, gemcitabine, docetaxel, irinotecan, or etoposide administered at least 180 days after radiotherapy or surgery on the lung parenchyma; OR (3) first-ever administration of cytotoxic chemotherapeutics and no history of radiation therapy or surgery on the lung parenchyma; (4) conditions (1), (2), and (3) began after January 1 2011; and (5) observation duration of at least 6 months. In total, 29,174 patients were found to have been diagnosed with stage IIIB or IV NSCLC and received palliative chemotherapy.
In the third query, to identify patients with brain metastasis of newly diagnosed stage IIIB or IV NSCLC, the following operational definitions were used: (1) at least three consecutive brain imaging (magnetic resonance imaging or computed tomography) codes with brain metastasis (ICD-10, C793) in the absence of a history of treatment for brain metastasis or cerebrovascular events, OR (2) having brain surgery not for cerebrovascular events or a brain radiation therapy code, OR (3) regularly taking anticonvulsant drugs such as levetiracetam or valproic acid without a code for brain disease or brain surgery or brain radiation therapy, plus condition (1). The diagnostic codes and billing codes of all treatments and drugs are available in HIRA homepage (http://www.hira.or.kr). www.nature.com/scientificreports www.nature.com/scientificreports/ Definition of survival outcomes. The overall survival (OS) duration was calculated from the date of diagnosis to the date of death or the last follow-up visit. The date of diagnosis was defined as the date when first chemotherapy or surgery or radiotherapy was started after the first-ever application of the C34 diagnostic code. The date of death was extracted from the insurance dataset. If the date of death could not be identified and there were no verified records of visits to the outpatient or inpatient clinic for 6 months before May 31 2017, the patient was regarded as dead.
Statistical analysis. Baseline characteristics are presented as means (±standard error) and medians
(ranges) for continuous variables and frequencies (%) for categorical variables. A t-test was performed for comparisons of continuous variables and Pearson's chi-squared test or two-sample proportion z-test for comparisons of categorical variables. Kaplan-Meier method was performed to estimate the probability of brain metastasis (CC or TT failure) or survival. Unfortunately, the proportional hazards assumption was violated in this study. Poisson regression analysis, a type of generalized linear models, was performed to estimate relative risk (RR). The SAS Enterprise Guide version 6.1 (SAS Inc., Cary, NC, USA), Visual Basic for Applications 7.0 (Microsoft Inc., Redmond, WA, USA), and Excel 2010 (Microsoft Inc., Redmond, WA, USA) was used to perform data mining and statistical analyses.
Results
Incidence of brain metastasis in stage IIIB or IV NSCLC patients. Among 29,174 patients with newly diagnosed stage IIIB or IV NSCLC, 7,847 (26.9%) experienced brain metastasis. 6,716 (23.0%) (2,434 and 4,282 in the CC and TT groups, respectively) had initial brain metastasis. Among 1,126 patients with subsequent brain metastasis, 576 and 550 were in the CC and TT groups, respectively. The incidence of initial and subsequent brain metastasis was higher in the TT group than in the CC group (P < 0.0001); however, the time to brain metastasis development did not differ significantly between the TT and CC groups (P = 0.082) (Supplemental Table 1 ).
Baseline characteristics. Finally, 22,458 patients were selected for analysis of subsequent brain metastasis.
Their demographic features are listed in Table 1 . Of the patients, 16 ,119 (71.8%) received TT as their first-line treatment, while 6,339 (28.2%) received CC. Within an 8.6-month median follow-up period (range, 0-77.5 months), 1,126 (5.0%) patients developed subsequent brain metastasis.
Factors associated with subsequent brain metastasis. Younger age, female, and absence of chronic obstructive pulmonary disease (COPD) were identified as risk factors for subsequent brain metastasis. In addition, the use of TT compared to that of CC as a first-line treatment was a significant risk factor, likely because NSCLC patients with genetic mutations have a higher incidence of subsequent brain metastasis. After adjusting for all variables at baseline, the associations of the above risk factors with brain metastasis, except COPD, remained significant ( Table 2 ). overall cumulative incidence of subsequent brain metastasis according to systemic treatment. The overall cumulative incidence of subsequent brain metastasis was significantly higher in those who received TT than in those who received CC as the first-line treatment (1-year cumulative incidence, 2.4 ± 0.2% vs. 1.9 ± 0.2%; 3-year cumulative incidence, 18.6 ± 0.9% vs. 11.9 ± 0.6%; P < 0.0001; Fig. 3A) .
Notably, the overall cumulative incidence of brain metastasis during the initial 10 months of first-line treatment did not differ between two groups (Fig. 3B ). However, after 10 months of first-line treatment, the overall cumulative incidence of brain metastasis was higher in the patients who received TT until the start of second-line treatment (TT vs. CC; 1-year cumulative incidence, 2.8 ± 0.3% vs. 1.4 ± 0.2%; 2-year cumulative incidence, 8.2 ± 0.7% vs. 3.3 ± 0.6%; P < 0.0001; Fig. 3B ). Next, we analyzed whether brain metastasis occurred during or after the second-line treatment period among patients who did not have brain metastasis during first-line treatment. The cumulative incidence of brain metastasis during or after second-line treatment was higher in EGFR/ALK TKI-failed patients than in CC-failed patients (TT vs. CC; 1-year incidence, 10.3 ± 0.9% vs. 4.2 ± 0.3%; 3-year, 37.0 ± 3.1% vs.18.6 ± 1.0%; respectively, P < 0.0001; Fig. 3C ).
The cumulative incidence of brain metastasis during first-line treatment did not differ according to the first-line EGFR TKI applied (P = 0.283; Supplemental Fig. 2A ). The cumulative incidence of brain metastasis during or after second-line treatment was significantly higher in the gefitinib-failed patients than in the erlotinib-failed patients (P = 0.081; Supplemental Fig. 2B ).
Factors associated with survival outcomes.
Patients who developed subsequent brain metastasis had a higher RR for survival than those who did not (unadjusted RR, 1.089 (1.125-1.053), P < 0.0001; adjusted RR, 1.250 (1.208-1.294), P < 0.0001; Table 3 ). Patients in the TT group (median OS duration, 14.9 months; 95% CI, 14.3-15.4; 5-year OS rate, 11.6%) had significantly better survival outcomes compared to those in the CC group (median OS duration, 6.8 months; 95% CI, 6.6-7.0 months; 5-year OS rate, 9.2%, P < 0.0001) (Supplemental Fig. 3 ).
Brain metastasis, older age, male sex, anticoagulant use, COPD and first-line CC were identified as risk factors for poor survival outcomes. The effect of risk factors remained significant even after adjusting for baseline variables, except anticoagulant use and COPD.
Discussion
We investigated the incidence of brain metastasis in NSCLC patients who received CC and TT as the first-line treatment. The overall prevalence of brain metastasis was 26.9% among stage IIIB or IV NSCLC patients who received palliative systemic treatment; of these patients without initial brain metastasis, 5.0% subsequently developed brain metastasis. Because of the characteristics of the HIRA database and the coverage by national insurance of first-line EGFR TKIs only for patients with EGFR mutations after 2011 in South Korea, patients who received TT as their first-line treatment were regarded as having genetic aberration. The overall cumulative incidence of brain metastasis was significantly higher in patients regarded as having genetic aberrations than in those without them. In addition to the first-line TT, younger age, and female sex were risk factors for subsequent brain metastasis.
NSCLC patients harboring EGFR mutations are reported more likely to have brain metastases 4, [8] [9] [10] [11] [12] [13] [14] . In our study, the overall incidence of brain metastasis among patients in the TT group (regarded as having aberrations of EGFR/ ALK genes) was 32.7%, compared to 20.1% in the CC group (regarded as having wild-type EGFR/ALK genes). These rates are similar to the 31.4% and 19.7% of Japanese patients with mutated and wild-type EGFR, and the 37.0% and 21.5% of Korean patients, respectively 8, 11, 12 . Similarly, the frequency of initial brain metastasis was higher in the TT (27.4%) group than in the CC group (17.9%). In accordance with our results, the incidence of initial brain metastasis in EGFR mutation patients is reportedly 19-27%, compared to 9-22% in EGFR wild-type patients 4, 9, 10 . Moreover, the cumulative incidence of subsequent brain metastasis was significantly higher in the TT group (5.3%) than in the CC group (2.2%), which is also comparable to previous studies 4 . Notably, the presence of the EGFR exon19 or L858R point mutations, which accounted for 90% of the EGFR mutations, is predictive of subsequent brain metastasis 13 . In vitro, overexpression of mutated EGFR induces morphological changes toward a mesenchymal phenotype and promotes the mobility of lung cancer cells 13 , implying that NSCLC patients with EGFR mutations have a higher probability of distant metastasis than do those with wild-type EGFR. Thus, first-line TT usage, which means the patients presumed to have gene aberrations, was a risk factor for initial and subsequent brain metastasis.
First-generation EGFR TKIs such as gefitinib and erlotinib show marked intracranial activity against the development and progression of brain metastasis in patients with mutated EGFR [15] [16] [17] [18] [19] . The combined analysis of LUX-Lung 3 and 6 trials, afatinib, a second-generation EGFR TKI significantly improved progression-free survival in patients with NSCLC plus brain metastases and common EGFR mutations (8.2 vs. 5.4 months; hazard ratio, 0.50) 20 . In a retrospective study, NSCLC patients who responded to EGFR TKIs showed the 1-and 2-year CNS failure rates of 14% and 36% 21 . In our study, the 1-and 3-year cumulative incidences were 2.4% and 18.6%, respectively. However, treatment modalities of brain metastases and the characteristics of the study subjects differed among each study. Thus, well-designed large-scale observational cohort studies are needed to clarify the patterns of brain metastasis in NSCLC patients with EGFR/ALK aberrations. www.nature.com/scientificreports www.nature.com/scientificreports/ After failure of the first-line treatment, the incidence of brain metastasis increased in the TT group compared to the CC group. Acquired resistance mutations and the flare phenomenon likely explain such rapid progression 22 . This increase of brain metastasis was frequently observed in the patients who received gefitinib as the first-line treatment than in those who received erlotinib. The serum concentration of TKIs is important to overcome their incomplete BBB penetration to effectively control cancer cells with EGFR mutations in the brain 23 . The approved dose of erlotinib is determined as its maximum tolerated dose (MTD), whereas gefitinib is used at approximately one-third of its MTD 24 . Inefficient elimination of EGFR-mutant cancer cells by gefitinib' lower CNS concentration than erlotinib's may explain the higher incidence of brain metastases after failure of gefitinib compared to erlotinib.
The risk factors for subsequent brain metastasis were younger age, female sex, as well as TT usage as the first-line treatment. In the Surveillance, Epidemiology, and End Results data, the incidence of brain metastasis is higher in female patients and those <60 years of age 25 . Females with lung cancer are more likely than males to be never-smokers, have adenocarcinoma with an activating EGFR or ALK mutation, which increase the risk of distant metastasis.
Several limitations to the present study are worth mentioning. There may have been bias in the stratification according to the clinical stage, molecular features or in the definition of brain metastasis. Because the patients' data was derived from the HIRA database and ICD-10 code, the information regarding stage, the molecular features, the presence of brain metastasis, the progress of the disease and causes of death had to be inferred by the treatment pattern. However, to overcome any such bias we used a strict multistep approach for selection of appropriate patient cohort.
In conclusion, our results imply that the overall cumulative incidence of brain metastasis was significantly higher in patients received TT, regarded as having EGFR/ALK mutations, than in those not having EGFR/ALK mutations, although TT effectively inhibits the development of brain metastasis until 10 months of first-line treatment. In patients with EGFR/ALK mutations after TT failure, regular screening for brain metastasis and its treatment with agents that can penetrate the BBB and overcome resistance are needed. 
